<DOC>
	<DOCNO>NCT01631435</DOCNO>
	<brief_summary>This prospective , multi-center ( 6 site ) study aim To establish effectiveness PillCam Platform PillCam Crohn 's capsule demonstrate visualize small bowel colon patient active symptom associate Crohn 's disease ( CD ) .</brief_summary>
	<brief_title>PillCam® Platform With PillCam Crohn 's Disease Capsule</brief_title>
	<detailed_description>This prospective , multi-center ( 6 site ) study aim evaluate diagnostic yield safety PillCam Platform CD capsule subject symptoms associate Crohn 's disease . All subject enrol study evidence active symptom associate Crohn 's disease . Each subject require follow bowel preparation regimen undergo Crohn 's Disease capsule endoscopy procedure thereafter ileocolonoscopy procedure day . The ileocolonoscopy procedure may do follow day per physician discretion . If ileocolonoscopy procedure do within 24 hour CE procedure , subject stay clear liquid diet . Observations/ assessment conduct trial detailed section : Visit 1 ; Screening visit - Informed consent process - screening eligibility participate study - Inclusion/exclusion criterion - Small bowel patency test - Demographic data - Pregnancy test - General medical history Visit 2 ; PillCam® Crohn 's capsule ingestion - PillCam® CD bowel preparation - Capsule endoscopy Conventional ileocolonoscopy Examination ( day within 24 hour ) - Ileocolonoscopy intubation terminal ileum Follow period ( 5-9 day follow visit 2 ) • CE Follow telephone contac</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1 . Subject age 1875 year , inclusive 2 . Subject known CD sign symptom active disease include one following : Chronic diarrhea Chronic abdominal pain Rectal bleeding 3 . Subject least one follow within three month enrollment : Positive inflammatory marker ( ESR , CRP , thrombocytosis , leukocytosis , fecal lactoferrin , fecal alpha1 antitrypsin ) Anemia ( hemoglobin level normal reference range ) Hypoalbuminemia ( albumin normal reference range ) Weight loss 4 . Proven patency Agile capsule another approach deem clinically acceptable investigator , e.g . CT enterography , perform within 90 day prior enrollment . 5 . Subject agree sign consent form 1 . Indeterminate Colitis 2 . Ulcerative Colitis 3 . Antibiotic Associated Colitis 4 . Stool positive Ova &amp; Parasite Clostridium difficile toxin within 3 month enrollment 5 . Other know infectious cause increase symptom 6 . Known history intestinal obstruction current obstructive symptom , severe abdominal pain accompany nausea vomiting , base investigator judgment . 7 . Definite long stricture see radiological exam . 8 . Nonsteroidal antiinflammatory drug include Aspirin , ( twice weekly ) 4 week precede enrollment 9 . Suspected GI stricture , follow Pillcam Patency study image study could prove patency GI tract . 10 . Subject prior abdominal surgery gastrointestinal tract last 6 month , uncomplicated procedure would unlikely lead bowel obstruction base clinical judgment investigator . 11 . Subject expect undergo MRI examination within 7 day ingestion capsule . 12 . Subjects know suspected delayed gastric empty 13 . Subjects know suspected delay Small bowel motility 14 . Subject suffers condition , swallow problem , precludes compliance study and/or device instruction . 15 . Subject Type I Type II Diabetes . 16 . Subject allergy know contraindication medication use study . 17 . Subject condition , preclude compliance study and/or device instruction . 18 . Women either pregnant nursing time screening , childbearing potential practice medically acceptable method contraception . 19 . Concurrent participation another clinical trial use investigational drug device . 20 . Subject suffers life threaten condition . 21 . Subject history clinical evidence renal disease and/or previous clinically significant laboratory abnormality renal function parameter .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>All subject evidence active symptom associate Crohn 's disease</keyword>
</DOC>